Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eylea's Dosing Regimen Is Key Question As FDA Takes Draft Labeling To Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory panel to consider a bi-monthly dosing scheme for Regeneron's wet AMD and how to handle potential elevations in intraocular pressure at June 17 meeting.

You may also be interested in...

Regeneron/Bayer's Wet AMD Drug Goes Before FDA Panel In June

Regneron and Bayer likely to tout aflibercept's better dosing schedule over Lucentis and may seek further differentiation in wake of Lucentis v. Avastin study.

Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.

Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee

Positive results of two Phase III studies show VEGF Trap-Eye candidate has potential for dosing every two months, but competing against Roche's Lucentis and off-label Avastin won't be easy.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts